Gilead Builds Japan Oncology Presence With Trodelvy

Yescarta Also Back In House

 
• By Lisa Takagi
  
Gilead aims to launch Trodelvy in Japan in 2024, where its Phase III for TNBC and lung cancer has been ongoing .
Gilead aims to launch Trodelvy in Japan in 2024, where its Phase III for TNBC and lung cancer has been ongoing. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Japan

More from Focus On Asia